Katima Mulilo — Almost three years ago, the privately funded Mapilelo ('Place of Survival') project began providing people in the impoverished northeastern Caprivi region with anti-AIDS drugs.
But with pharmaceutical company Bristol-Myers Squibb (BMS) announcing the end of its funding in September, concerns have been raised over the future of the project, which has about 1,700 people on antiretroviral (ARV) medication.
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article